CTCL Detection via WES and Single-Cell RNAseq
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for advanced stage cutaneous T-cell lymphoma (CTCL) are inadequate, with limited response to monotherapy and compartmentalized responses in the skin and blood, highlighting a need for therapeutic targets in the skin compartment.
Innovation Solution
The use of whole exome sequencing (WES), parallel single-cell RNA sequencing (RNAseq), and copy number variation (CNV) interference assays to detect malignant cells in the tumor microenvironment, identifying specific gene expression patterns and mutations indicative of CTCL, and administering anti-cancer agents such as OXPHOS, Myc, and CDK4/6 inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If whole exome sequencing and single-cell RNAseq are performed to detect malignant cells, then measurement precision of malignancy detection is improved, but device complexity and cost increase
Solution Approach 1:
The patent divides the complex detection process into distinct methodological components: whole exome sequencing for mutation detection, single-cell RNAseq for gene expression profiling, and CNV interference assays for copy number variation analysis. Each component targets specific molecular features of malignant cells, allowing the complex diagnostic challenge to be broken into manageable analytical segments that can be performed sequentially or in combination
Solution Approach 2:
The patent applies multiple sequencing and analysis methods to the same tissue sample, enabling a single biopsy to provide comprehensive information about mutations, gene expression patterns, and copy number variations. This multi-functional approach to sample analysis improves detection precision without requiring multiple separate biopsies or procedures
2Measurement precision
If multiple gene expression patterns and mutations are analyzed to identify CTCL, then measurement precision of cancer detection is improved, but difficulty of detecting and measuring increases
Solution Approach 1:
The patent performs whole exome sequencing and single-cell RNAseq on archived tissue samples from previous clinical studies, allowing retrospective analysis of gene expression patterns and mutations without requiring new patient procedures. This preliminary collection and preservation of biological samples enables comprehensive molecular characterization when needed for diagnostic clarification
3Measurement precision
If compartmentalized responses in skin and blood are monitored, then measurement precision of treatment response is improved, but loss of time for monitoring increases
Solution Approach 1:
The patent uses circulating tumor cells and tumor DNA in peripheral blood as liquid biopsy intermediaries to monitor treatment response. These blood-based markers serve as accessible proxies for tumor burden and response, allowing clinicians to assess treatment efficacy without requiring repeated invasive skin biopsies or extensive imaging procedures
Data Source
AI summary
Disclosed novel expression and mutation patterns that correlate with the presence of a malignancy in B and T cell cancers. Accordingly, disclosed herein are kits and methods for the diagnosis of cancer malignancies.